Spain’s €18M push targets health inequality that has affected women for over a century

The Spanish Government has announced a new national programme allocating approximately €18 million annually to research into diseases and health conditions that affect women specifically or disproportionately, in a move aimed at addressing long-standing inequalities in biomedical science.

The initiative was formally presented on June 15  by Prime Minister Pedro Sánchez and the Minister for Science, Innovation and Universities, Diana Morant, under the programme titled “Somos. Contamos: fin de la discriminación de las mujeres en la investigación de la salud” (“We Matter. We Count: ending discrimination against women in health research”).

Officials say the plan represents a structural shift in Spain’s scientific priorities, targeting areas where women have historically been underrepresented in clinical trials, medical datasets and research design. This imbalance has contributed to delayed diagnoses, reduced treatment accuracy and persistent health inequalities affecting millions of women.

Policy shift and funding structure

Officials say the programme represents a structural shift in Spain’s scientific priorities, targeting areas where women have historically been underrepresented in clinical trials, medical datasets and research design. This imbalance has contributed to delayed diagnoses, reduced treatment accuracy and persistent health inequalities affecting millions of women.

Funding will be distributed annually through key national research bodies, including the Instituto de Salud Carlos III (Carlos III Health Institute) and the Centro para el Desarrollo Tecnológico y la Innovación (Centre for the Development of Industrial Technology).

The programme will also introduce new doctoral and postdoctoral research contracts focused on women’s health, aiming to strengthen long-term scientific capacity in this field.

Tackling historic under-investment in women’s health

The Government has described the initiative as a response to what it calls historic under-investment in women’s health research, where medical science has traditionally prioritised male biological models.

Priority research areas include endometriosis, autoimmune diseases, hormonal disorders, cardiovascular conditions and mental health disorders, all of which disproportionately affect women or present differently in female patients.

Officials say improving representation in biomedical research is essential to ensuring earlier diagnosis, more accurate treatment pathways and better prevention strategies.

How the €18 million funding will be used

The annual investment will be distributed through competitive research calls and institutional funding channels.

• CDTI will support innovation projects linking research with industrial applications 
• The Carlos III Health Institute will fund biomedical and public health research 
• New academic pathways will be created for early-career researchers specialising in women’s health 

The Government also plans to strengthen cooperation between universities, hospitals and research centres, aiming to accelerate the translation of research findings into clinical practice.

What it means for millions of women in Spain

For women across Spain, the programme could have significant long-term consequences for healthcare outcomes.

Medical professionals have long warned that insufficient sex-specific research has contributed to misdiagnosis and delayed treatment in several conditions. Cardiovascular disease, for example, often presents differently in women than in men, leading to missed or late diagnoses. Similar issues are also seen in chronic pain conditions, autoimmune diseases and mental health disorders.

By increasing targeted research investment, the Government aims to improve clinical understanding and ensure more accurate medical guidance.

In practical terms, this could lead to:

• Earlier and more accurate diagnosis 
• More personalised treatment approaches 
• Improved understanding of disease progression in women 
• Greater inclusion of women in clinical trials and datasets 

Public reaction

The announcement has prompted widespread discussion online, with many highlighting the importance of addressing long-standing gaps in women’s healthcare and describing the programme as a potentially significant shift in how female health conditions are diagnosed and treated.

One commenter, Sarah from Málaga, said:

“I think this is a huge step for women. It’s long been known that the majority of research was done on men so when a woman would show up with different symptoms outside the box, they were usually just sent home with an incorrect diagnosis.”

Another reaction comes from from Marta in Barcelona :

“I think this is very important, there are so many health issues women struggle with on a daily bases that doctors cant give a diagnosis to, for this day and age I think enough is enough.”

A third commenter, Miriam, added:

“They took 16 years to diagnose me with endometriosis, thats 16 years enduring pain, being given a paracetamol and sent home with ‘just a bad period’. If it was a men’s health condition they would have found the cure for it by now. I feel this programme can really turn things around for women and their health.”

Taken together, the responses reflect a broader sense of frustration among women about historical delays in diagnosis and under-researched conditions, alongside cautious optimism that targeted investment could begin to close those gaps.

Strengthening Spain’s wider science strategy

Government figures show rising investment in science and innovation since 2018, with increasing emphasis on biomedical research and long-term capacity building.

Officials argue that sustained funding is essential for improving public health resilience, particularly as the population ages and chronic conditions become more prevalent.

A long-term shift in research priorities

The initiative will run over multiple years, with annual evaluations conducted by national research agencies. Rather than focusing on isolated projects, the goal is to embed sex-based analysis into mainstream biomedical research and ensure it becomes a standard component of future scientific studies.

Authorities describe the programme as a structural change in how medical research is designed and funded. For millions of women, it represents the possibility of more accurate diagnosis, better-targeted treatments and a healthcare system that more consistently reflects their medical reality.